India markets open in 7 hours 44 minutes
  • BSE SENSEX

    52,474.76
    +174.26 (+0.33%)
     
  • Nifty 50

    15,799.35
    +61.55 (+0.39%)
     
  • Dow

    34,479.60
    +13.40 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.12 (+0.35%)
     
  • BTC-INR

    2,760,076.50
    +143,510.50 (+5.48%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • Hang Seng

    28,842.13
    +103.23 (+0.36%)
     
  • Nikkei

    28,948.73
    -9.87 (-0.03%)
     
  • EUR/INR

    88.4391
    -0.5864 (-0.66%)
     
  • GBP/INR

    103.1023
    -0.5207 (-0.50%)
     
  • AED/INR

    19.8950
    +0.0360 (+0.18%)
     
  • INR/JPY

    1.4944
    +0.0020 (+0.13%)
     
  • SGD/INR

    55.2520
    +0.0120 (+0.02%)
     

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.

Participants may access a live webcast of the event through the following link:
https://event.on24.com/wcc/r/3173547/7EB680169FF01818435F231AA17B51A2.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com